Navigation Links
Dr. Joan Fallon, Curemark CEO, Addresses Keystone Symposia Meeting On Autism
Date:5/3/2010

RYE, N.Y., May 3 /PRNewswire/ -- Dr. Joan Fallon, founder and CEO of Curemark, LLC, (www.curemark.com), a drug research and development company focused on the treatment of neurological diseases, presented at the Keystone Symposia meeting, Toward Defining the Pathophysiology of Autistic Behavior, held in April in Snowbird, Utah.  

Fallon presented on "The Role of Protein Assimilation and Utilization in Children with Autism."  She discussed Curemark's research exploring a possible link between a lack of protein-digesting enzymes in autistic children, necessary for the production of amino acids needed for brain function, and the symptoms of autism.  

"The Keystone Symposia meeting provided an excellent forum to share our research with others in the scientific community who are attempting to understand the physiological causes of autism and working to develop possible therapies," Fallon said.

Curemark is in the midst of Phase III clinical trials for CM-AT, its autism treatment targeted as enzyme replacement therapy.  CM-AT recently was designated as a Fast Track drug by the FDA.

Keystone Symposia on Molecular and Cellular Biology is a non-profit organization with a 38-year history of organizing conferences to connect the scientific community and accelerate scientific discoveries.

About CUREMARK LLC

Curemark is a drug research and development company focused on the treatment of neurological and other diseases, especially those with dysautonomic components, by addressing certain key gastrointestinal/pancreatic secretory deficiencies. The company's initial products are based upon breakthrough observations by its founder, Dr. Joan Fallon, which revealed a lack of protein digestion in children with autism and ADHD. To learn more about our innovative science, visit www.curemark.com

Safe Harbor Statement

This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. These forward-looking statements include, without limitation, statements regarding the mechanism of action of CM-AT, its potential advantages, its potential for use in treating autism, as well as the timing, progress and anticipated results of the clinical development and regulatory processes concerning CM-AT. These statements are based on our current beliefs and expectations as to such future outcomes, and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a material difference include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of CM-AT, our ability to finance our development of CM-AT, regulatory risks, and our reliance on third party researchers and other collaborators. We assume no obligation to update these statements, except as required by law.


'/>"/>
SOURCE Curemark LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Curemark Adds UC Davis MIND Institute to Autism Clinical Trial Sites
2. Curemark CM-AT Autism Treatment Granted FDA Fast Track Status
3. Curemark Enrolling Patients In Phase III Autism Trials At Ten Sites
4. Curemark Opens Patient Enrollment for Autism Treatment at Three More Clinical Trial Sites
5. Curemark Enrolls First Patients in Phase III Clinical Trials for Autism Treatment
6. Curemark Announces Senior Executive Promotions
7. Curemark CEO Presents at Epigenomics Conference
8. Curemark Closes Series A Financing
9. Curemark Appoints Preeminent Pediatrics Gastroenterologist
10. Baxa Addresses Health-System Capital Shortage With New Programs for IntelliFlowRx(TM) and IntelliFill i.v.(R)
11. WBAL Radio Segment With Dr. Leigh Vinocur Addresses Hope for the Rosacea Sufferer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... Tie-up with Government hospitals as ... to save newborns   Fortis La Femme, ... collaboration with Breast Milk Foundation (BMF), a non-profit organization within ... Bank, ,Amaara, in Delhi-NCR today. This non-profit centre recognizes that ... and should be available to babies deprived of mother,s milk.  ...
(Date:4/27/2016)... April 27, 2016 Oasmia ... developer of a new generation of drugs within ... survival results for Paclical/Apealea in the Phase III ... with epithelial ovarian cancer. These preliminary results showed ... combination with carboplatin versus Taxol in combination with ...
(Date:4/26/2016)... , April 26, 2016 Diplomat Pharmacy, ... of Jennifer Hagerman , Pharm D., to Vice ... growing role at Diplomat, Hagerman will continue to lead ... company that delivers custom education and training to Diplomat ... specialty pharmacy industry. Diplomat University also houses the quality ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... ... Dr. Robert Mondavi, one of the dentists in Torrance , is now ... as more patients are discovering the many different ways they can change and improve ... to them and which ones might work for their smiles. , “One of ...
(Date:4/29/2016)... ... April 29, 2016 , ... Reltok Nasal Products proudly announces that Boston ... and neck/ear, nose and throat specialty, has added the KOTLER NASAL AIRWAY™ to its ... is a newly patented safety device secured by nasal surgeons onto the floor ...
(Date:4/29/2016)... ... April 29, 2016 , ... Jvion, the market ... funding led by Eastside Partners, with participation from existing investor Martin Ventures. ... and accelerate its technology and product roadmap. , “Jvion is experiencing ...
(Date:4/29/2016)... ... April 29, 2016 , ... Regenerative Medicine Solutions (RMS) scored ... satisfaction survey, earning them second place for Tampa’s Best Places to Work. They were ... “This is a great accomplishment for our team,” says RMS Human Resources Manager Irene ...
(Date:4/29/2016)... Newport Beach, CA (PRWEB) , ... April 29, 2016 , ... ... Dr. Jane L. Frederick, Dr. Sanaz Ghazal, and Dr. Daniel A. Potter -- are ... the Society for Assisted Reproductive Technology (SART). In April, SART published the ...
Breaking Medicine News(10 mins):